SCHEMBL22799371

SCHEMBL22799371

CC1(C)OC2C(O)C[C@@H](COC(=O)c3ccccc3)O[C@@H]2O1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.65
▸ HPGD P15428 1/20 0.54
▸ POLB P06746 2/20 0.49
▸ GAA P10253 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ NPC1 O15118 1/20 0.46
▸ CES2 O00748 1/20 0.43
▸ PPM1B O75688 1/20 0.42
▸ MEN1 O00255 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNA5 P30532 1/20 0.39
▸ CHRNA7 P36544 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39
▸ SYNJ2 O15056 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20444803 1.00 ALDH1A1 (0.65) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL22799620 1.00 ALDH1A1 (0.65) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL26811910 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL13675166 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL13871579 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL17822523 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL3257710 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL7892319 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL7257546 0.85 ALDH1A1 (0.59) ALDH1A1HPGDPOLBGAAMAPK1
SCHEMBL24674007 0.83 ALDH1A1 (0.58) ALDH1A1HPGDPOLBGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES JANSSEN PHARMACEUTICA NV (BE) 2022-09-01 — — US disclosed
WO-2020249663-A1 NOVEL SPIROBICYCLIC INTERMEDIATES JANSSEN PHARMACEUTICA NV (BE) 2020-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220275018-A1 NOVEL SPIROBICYCLIC INTERMEDIATES NME2, SLC28A1, SLC28A2 ALDH1A1 248/4885HPGD 258/4885POLB 205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback